title: Dexrazoxane for the treatment of chemotherapy-related side effects.
abstract: For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.
authors.affiliation: Thoracic and Neuroendocrine Section, Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark.
authors.forename: Seppo W
authors.initials: SW
authors.lastname: Langer
keywords: anthracyclines; cardiomyopathy; extravasation